Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 20;75(7):ftx083. doi: 10.1093/femspd/ftx083

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© FEMS 2017. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 1. — Forest plot of prophylaxis RCTs morbidity data sorted by antimicrobial class and control group attack rates. Random-effects meta-regression model RR predictions represented as shaded grey and black diamonds. AttRate—control group attack rate % (CER%); antimicrobials investigated included macrolides (tylosin, tilmicosin, tulathromycin, gamithromycin, tildipirosin), tetracyclines (oxytetracyline, chlortetracycline, doxycycline), amphenicols (florfenicol), cephalosporins (ceftiofur), sulfonamides (sulfadimethoxine, sulfamethazine, trimethoprim sulphonamide), and fluoroquinolones (enrofloxacin), tetracycline combinations (oxytetracyline and/or chlortetracycline + neomycin, or sulfadimethoxine and/or sulfamethazine).